Arq, Inc. Shares Surge: ZORYVE Cream Data Impresses at RAD 2025

Arq, Inc. rose 2.43% intraday, with the company presenting new long-term results of ZORYVE cream at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference. The data demonstrated durable improvement in the signs and symptoms of atopic dermatitis, including almost half of participants achieving no or minimal itch with ZORYVE cream. The study also showed a consistent efficacy, safety, and tolerability profile observed with ZORYVE cream.